{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Endocrinology & Hormones > BicalutamideCAS：90357-06-5
Molecular Formula：C18H14F4N2O4S
Molecular Weight：430.37
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 90357-06-5 |
| Name | Bicalutamide |
| Molecular Formula | C18H14F4N2O4S |
| Molecular Weight | 430.37 |
| Solubility | Soluble in DMSO |
| Purity | HPLC≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 200-001-8 |
| MDL | MFCD00869971 |
| SMILES | FC1=CC=C(S(=O)(CC(O)(C(NC2=CC=C(C#N)C(C(F)(F)F)=C2)=O)C)=O)C=C1 |
| InChIKey | LKJPYSCBVHEWIU-UHFFFAOYSA-N |
| InChI | InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25) |
| PubChem CID | 2375 |
| Target Point | Androgen Receptor |
| Passage | Endocrinology & Hormones |
| Background | Bicalutamide is a nonsteroidal androgen receptor inhibitor. |
| Biological Activity | Bicalutamide (ICI-176334) 是一种androgen receptor (AR)拮抗剂，在LNCaP/AR(cs)细胞系中IC50为0.16 μM。Bicalutamide 可诱导自噬。[1] |
| In Vitro | Bicalutamide 经过一个拮抗剂到激活剂的转变，刺激AR活性。在缺乏合成雄激素R1881的情况下，Bicalutamide处理LNCaP/AR(cs)细胞，改变基因表达，与其记录的良好激活剂活性相符合。Bicalutamide诱导细胞增殖，这种作用存在剂量依赖性，且只部分抗R1881的效果。Bicalutamide 处理呀显著产生大量核AR，虽然比R1881处理的少。Bicalutamide通过诱导DNA在AR靶基因结合，而具有部分激活剂活性，且不完全抗 R1881的效果。在R1881存在时，Bicalutamide部分激活 VP16-AR调节的转录，指导AR 结合到DNA上。使用AR驱动的荧光素酶报告结构稳定整合到LNCaP/AR-luc细胞中。在R1881存在时，Bicalutamide只微弱且部分抗 VP16-AR调节的转录，IC50 为 0.35 μM。[1] 微摩尔 Bicalutamide显著降低集落形成，这种作用存在剂量依赖性。[2] 双重抑制 AR 和 mTOR信号通路产生进一步好处，在体外，Ridaforolimus-Bicalutamide联用作用于前列腺癌细胞，与单独药剂处理相比，产生协同抗增殖效果。[3] |
| In Vivo | Bicalutamide按规定的次最大剂量单独处理，降低79%肿瘤生长。Ridaforolimus-Bicalutamide 联用具有改进的和有效的抗肿瘤活性，几乎完全废除肿瘤生长。联合使用具有良好耐受性，在处理过程中体重没有明显改变。联用处理的小鼠中，血浆PSA水平与肿瘤生长紧密相关。[3] |
| Animal Experiment | Animal Models: 携带C4-2细胞的雄性裸鼠; Dosages: 10 mg/kg; Administration: 口服处理[3] |
| Kinase Experiment | Whole-cell competitive binding assays are performed in LNCaP/AR(codon-switch)(LNCaP/AR(cs))(harbors a mixture of exogenous wild-type AR and endogenous mutant AR(T877A))and cells propagated in Iscove's or RPMI media supplemented with 10% fetal bovine serum，or during the assay with 10% charcoal-stripped，dextran-treated fetal bovine serum(CSS). Cells are pre-incubated with 18F-FDHT，increasing concentrations(1pM to 1μM)of cold Bicalutamide are added，and the assay is performed to measure specific uptake of 18F-FDHT(4). IC50 values are determined using a one site binding model with least squares curve fitting and R2 > 0.99.[1] |
| Data Literature Source | [1] Clegg NJ，et al. Cancer Res. 2012，72(6)，1494-1503. [2] Colquhoun AJ，et al. Prostate Cancer Prostatic Dis. 2012. [3] Squillace RM，et al. Int J Oncol. 2012. |
| Unit | Bottle |
| Specification | 50mg 10mM*1mL in DMSO 100mg |
Bicalutamide是非甾体雄激素受体抑制剂。
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
